Jorgen Wittendorff
Geen lopende functies
Profiel
Jorgen Wittendorff formerly worked at Ablynx NV, as Senior Director-CMC & Supply from 2016 to 2019, Silence Therapeutics Plc, as Senior Vice President & Head-Manufacturing, and Ferring Pharmaceuticals A, as Vice President-Pharmaceutical Development from 1995 to 2016.
Mr. Wittendorff received his graduate degree from the University of Copenhagen.
Eerdere bekende functies van Jorgen Wittendorff
| Bedrijven | Functie | Einde |
|---|---|---|
| SILENCE THERAPEUTICS PLC | Corporate Officer/Principal | 06-02-2023 |
| ABLYNX | Corporate Officer/Principal | 01-01-2019 |
Ferring Pharmaceuticals A/S
 Ferring Pharmaceuticals A/S Pharmaceuticals: MajorHealth Technology Ferring Pharmaceuticals A/S specializes in the development, production and marketing of pharmaceutical products. It offers products in the fields of urology, infertility, obstetrics, gynecology, gastroenterology and maternal health. The company is headquartered in Copenhagen, Denmark. | Corporate Officer/Principal | 01-01-2016 |
Opleiding van Jorgen Wittendorff
| University of Copenhagen | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| SILENCE THERAPEUTICS PLC | Commercial Services |
| Bedrijven in privébezit | 2 |
|---|---|
Ferring Pharmaceuticals A/S
Ferring Pharmaceuticals A/S Pharmaceuticals: MajorHealth Technology Ferring Pharmaceuticals A/S specializes in the development, production and marketing of pharmaceutical products. It offers products in the fields of urology, infertility, obstetrics, gynecology, gastroenterology and maternal health. The company is headquartered in Copenhagen, Denmark. | Health Technology |
Ablynx NV
 Ablynx NV BiotechnologyHealth Technology Ablynx NV operates as a clinical stage biopharmaceutical company, which engages in the development of proprietary therapeutic proteins under the Nanobodies brand. It includes haematology, inflammation, infectious disease, autoimmune disease, oncology and immune-oncology. The company was founded by Mark Vaeck in 2001 and is headquartered in Ghent, Belgium. | Health Technology |
